Loading…
VALN
Valneva SE
NASDAQ· Healthcare· Biotechnology· CUSIP 92025Y103
$6.43-2.28%Price as of Aug 29, 18:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $609.71M
- P/E
- —
- Forward P/E
- 5.4x
- P/B
- 6.4x
- Dividend yield
- —
- Payout
- —
- EPS
- -$2.07
- ROE
- -117.85%
- Profit margin
- -110.29%
- Revenue growth
- -27.70%
- Beta
- 1.35
- 52-week high
- $12.23
- 52-week low
- $4.75
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -86.2% over 5Y.
today you would have $195.54▼ -80.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $8.82 | $4.37 | $10.37 | $12.72 | |
| P/S | 6.8x | 8.8x | 4.2x | 9.4x | 4.9x |
| P/B | 9.6x | 14.4x | 3.9x | 11.2x | 8.0x |
| EPS | -$1.36 | -$0.16 | -$1.46 | -$2.48 | |
| Profit margin | -52.80% | -65.95% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CRMDCorMedix Inc. | $7.78 | 3.6x | 1.3x | — | 54.93% | $606.41M |
| CTMXCytomX Therapeutics, Inc. | $2.78 | — | 2.0x | — | -37.75% | $605.76M |
| PHRPhreesia, Inc. | $9.68 | 53.8x | 1.6x | — | 3.12% | $600.85M |
| ALTAltimmune, Inc. | $3.19 |
About the company
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; PF-07307405, a vaccine candidate to prevent Lyme disease cases in individuals aged five years and older and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.
- 620
- Saint-Herblain, France
Company description provided by Yahoo Finance.